PHARMACOGENOMICS IN DRUG DEVELOPMENT

PHARMACOGENOMICS IN DRUG

DEVELOPMENT

TABLE OF CONTENTS

·Introduction to Pharmacogenomics

·Brief Overview of Pharmacogenomics

·Importance

·Principles

·Role in drug development

·Applications

·Benefits

·Challenges

·Future Directions & Opportunities

·Case Studies & Examples

·Conclusion

·References

INTRODUCTION

PHARMACOGENOMICS IS THE STUDY OF HOW GENES AFFECT A PERSON'S RESPONSE TO DRUGS.THIS FIELD COMBINES 
PHARMACOLOGY (THE SCIENCE OF DRUGS) AND GENOMICS (THE STUDY OF GENES AND THEIR FUNCTIONS)TO DEVELOP 
EFFECTIVE,SAFE MEDICATIONS THAT CAN BE PRESCRIBED BASED ON A PERSON'S GENETIC MAKEUP.

Brief Overview 

IMPORTANCE

·PHARMACOGENOMICS PLAYS A CRUCIAL ROLE IN DRUG DEVELOPMENT BY HELPING TO IDENTIFY INDIVIDUAL GENETIC VARIATIONS THAT INFLUENCE HOW A PERSON RESPONDS TO MEDICATIONS.THIS KNOWLEDGE ALLOWS FOR MORE TARGETED AND EFFECTIVE DRUG DEVELOPMENT,ULTIMATELY LEADING TO IMPROVED PATIENT OUTCOMES AND REDUCED HEALTHCARE COSTS.

PRINCIPLES OF PHARMACOGENOMICS

·1.GENETIC VARIATION INFLUENCES DRUG RESPONSE:INDIVIDUAL DIFFERENCES IN GENES,SUCH AS THOSE INVOLVED IN DRUG METABOLISM(E.G.,CYP ENZYMES) OR DRUG TRANSPORT,CAN LEAD TO VARIATIONS IN HOW A PERSON RESPONDS TO A PARTICULAR DRUG.

2.PHARMACOKINETICS AND PHARMACODYNAMICS:(A)PHARMACOKINETICS:PHARMACOGENOMICS STUDIES HOW A DRUG IS ABSORBED,DISTRIBUTED,METABOLIZED,AND EXCRETED (ADME) BY THE BODY,AND HOW THESE PROCESSES ARE AFFECTED BY GENETIC VARIATIONS.(B)PHARMACODYNAMICS:IT ALSO INVESTIGATES HOW DRUGS INTERACT WITH THIEIR TARGETS (E.G.,RECEPTORS,ENZYMES) AT THE CELLULAR AND MOLECULAR LEVEL,AND HOW THESE INTERACTIONS ARE INFLUENCED BY GENETIC VARIATIONS.

3.PERSONALIZED MEDICINE:BY UNDERSTANDING THE GENETIC FACTORS THAT INFLUENCE DRUG RESPONSE,PHARMACOGENOMICS ALLOWS FOR THE DEVELOPMENT OF PERSONALIZED TREATMENT PLANS,LEADING TO MORE EFFECTIVE AND SAFER THERAPIES.

4.IMPROVED DRUG EFFICACY AND SAFETY:PHARMACOGENOMICS HELPS IDENTIFY INDIVIDUALS WHO ARE MORE LIKELY TO BENEFIT FROM A PARTICULAR DRUG OR THOSE WHO MAY EXPERIENCE ADVERSE DRUG REACTIONS,ALLOWING FOR MORE TARGETED AND APPROPRIATE TREATMENT STRATEGIES.

·

5.DEVELOPMENT OF NOVEL THERAPIES:PHARMACOGENOMICS CAN ALSO GUIDE THE DEVELOPMENT OF NEW DRUGS BY IDENTIFYING POTENTIAL DRUG TARGETS BASED ON GENETIC VARIATIONS AND BY PREDICTING THE RESPONSE TO NEW DRUGS IN SPECIFIC POPULATIONS.

6.ETHICAL CONSIDERATIONS:PHARMACOGENOMICS RAISES ETHICAL QUESTIONS RELATED TO GENETIC TESTING,PRIVACY,AND THE POTENTIAL FOR DISCRIMINATION,WHICH NEED TO BE ADDRESSED.

7.INTEGRATION WITH OTHER FIELDS:PHARMACOGENOMICS IS AN INTERDISCIPLINARY FIELD THAT INTEGRATES GENETICS,PHARMACOLOGY,AND CLINICAL MEDICINE TO IMPROVE PATIENT CARE

APPLICATIONS

-TARGET IDENTIFICATION AND VALIDATION:

UNDERSTANDING HOW DRUGS INTERACT WITH BIOLOGICAL TARGETS TO PRODUCE THERAPEUTIC EFFECTS.

-DOSE-RESPONSE RELATIONSHIPS:

DETERMINING THE OPTIMAL DOSE RANGE FOR EFFICACY AND SAFETY.

- MECHANISM OF ACTION STUDIES:

ELUCIDATING HOW DRUGS WORK AT THE MOLECULAR AND CELLULAR LEVELS.

-EFFICACY PREDICTION:

PREDICTING DRUG EFFICACY IN HUMANS BASED ON PRECLINICAL MODELS.

TOXICITY PREDICTION:

IDENTIFYING POTENTIAL TOXICITIES AND OPTIMIZING DRUG CANDIDATES.

- PERSONALIZED MEDICINE:

DEVELOPING TAILORED THERAPIES BASED ON INDIVIDUAL RESPONSES TO DRUGS.

DRUG OPTIMIZATION:

OPTIMIZING DRUG CANDIDATES FOR IMPROVED EFFICACY,SAFETY,AND PATIENT OUTCOMES.

BENEFITS

·PHARMACOGENOMICS EVENTUALLY CAN LEAD TO AN OVERALL DECREASE IN THE COST OF HEALTH CARE BECAUSE OF DECREASES IN:

·(1)THIE NUMBER OF ADVERSE DRUG REACTIONS

·(2)THE NUMBER OF FAILED DRUG TRIALS

·(3)THE TIME IT TAKES TO GET A DRUG APPROVED

·(4)THE LENGTH OF TIME PATIENTS ARE ON MEDICATION

·(5) THE NUMBER OF MEDICATIONS

CHALLENGES

·1.DIFFICULTY OF FINDING SUITABLE BIOMARKERS

·2.HIGH COST OF GENETIC TESTING

·3.NEED FOR SPECIALIZED EXPERTISE IN DATA INTERPRETATION

·4.POTENTIAL FOR BIASED FINDINGS DUE TO LIMITED REPRESENTATION IN GENETIC DATABASES

·5.REGULATORY HURDLES,ETHICAL CONSIDERATIONS REGARDING INFORMED CONSENT AND DATA PRIVACY

6.COMPLEXITY OF INTEGRATING PHARMACOGENOMICS INFORMATION INTO EXISTING ELECTRONIC HEALTH RECORDS

FUTURE DIRECTIONS & OPPORTUNITIES

IN FUTURE,THE OPPORTUNITY TO FURTHER UNVEIL THE RELATIONSHIP BETWEEN ADME GENES AND DRUG RESPONSE,AS WELL AS IDENTIFYING NEW GENES INVOLVED IN THE EFFECTS AND/OR TOXICITY OF ANTICANCER DRUGS OR THE REPURPOSING OF DRUGS,COULD OPEN UP NEW AVENUES FOR FULLY IMPLEMENTING PGX IN THE CLINICAL SETTING.

CASE STUDIES & EXAMPLES

·1.WARFARIN:

GENETIC VARIATIONS IN VKORC1 AND CYP2C9 GENES AFFECT WARFARIN DOSING,AND GENETIC TESTING CAN GUIDE PERSONALIZED DOSING.

2.HER2-POSITIVE BREAST CANCER:

TRASTUZUMAB (HERCEPTIN) TARGETS HER2-POSITIVE BREAST CANCER CELLS,AND GENETIC TESTING IDENTIFIES PATIENTS LIKELY TO BENEFIT.

3.CYP2D6 AND CODEINE:

GENETIC VARIATIONS IN CYP2D6 AFFECT CODEINE METABOLISM,AND GENETIC TESTING CAN PREDICT EFFICACY AND RISK OF SIDE EFFECTS.

·4.ABACAVIR AND HLA-B _5701*:

GENETIC TESTING FOR HLA-B*5701 IDENTIFIES INDIVIDUALS AT RISK OF ABACAVIR HYPERSENSITIVITY,ALLOWING FOR ALTERNATIVE TREATMENT.

·5.INVOCATOR (KALYDECO) AND CYSTIC FIBROSIS:

THIS DRUG TARGETS SPECIFIC GENETIC MUTATIONS IN CYSTIC FIBROSIS,DEMONSTRATING THE POTENTIAL FOR PERSONALIZED MEDICINE.

CONCLUSION

·PHARMACOGENOMICS IN PHARMACEUTICAL INDUSTRY IS A POTENTIAL TOOL,AWAITING USE FOR THE MAXIMUM BENEFIT.CURRENTLY PHARMACOGENETIC METHODS ARE BEING USED WORLDWIDE,PARTICULARLY FOR ASSESSING THE SAFETY PROFILE OF DRUGS.